Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 146 matching trials from the live ClinicalTrials.gov search.
Completed Phase 4 Interventional Accepts healthy volunteers Results available

EXPAREL® for Pain After Tonsillectomy

NCT02444533
Conditions
Tonsillectomy, Tonsillitis, Post-operative Pain
Interventions
Liposomal Bupivacaine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Community Acquired Pneumonia (CAP), Sinusitis, Strep Pharyngitis, Acute Otitis Media (AOM)
Interventions
Online Educational Modules, Prescribing Feedback Reports, Clinical Decision Support, Live, hybrid in-person and online educational sessions
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 12 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Carcinoma, Oropharyngeal Squamous Cell Carcinoma (OPSCC), Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma (SCC), Oropharyngeal Squamous Cell Carcinoma (OPSCCA), Oropharyngeal Cancer, Oropharyngeal Squamous Cell Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma, HPV 16 Positive Oropharyngeal Tumors (OPC)
Interventions
Dose de-escalation to contralateral neck., Dose de-escalation to gross disease to contralateral neck, Dose de-escalation to gross disease, Circulating Tumor DNA test (ctDNA test)
Radiation · Diagnostic Test
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
4
States / cities
Baltimore, Maryland • Columbia, Maryland • Glen Burnie, Maryland
Conditions
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Melanoma, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, oxaliplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Arcadia, California
Conditions
Acute Sinusitis, Streptococcal Pharyngitis, Pneumonia, Viral Infection
Interventions
Antimicrobial Stewardship Bundle
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Influenza
Interventions
favipiravir, Placebo
Drug
Lead sponsor
MDVI, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
60
States / cities
Birmingham, Alabama • Hunstville, Alabama • Hot Springs, Arkansas + 48 more
Conditions
Tonsillitis, Obstructive Sleep Apnea of Child
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
3 Years to 12 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Human Papilloma Virus, Cervical Cancer, Human Papillomavirus Infection, Oropharyngeal Cancer, Vaginal Cancer, Vulvar Cancer, Anal Cancer, Penile Cancer
Interventions
WoW and BNI
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
9 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Tonsillitis, Sleep Disordered Breathing, Hernia, Hydrocele, Hypospadias, Undescended Testicle, Circumcision
Interventions
Disposal Aid
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Year to 17 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Pharyngitis
Interventions
Placebo, Flurbiprofen
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Storrs, Connecticut
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, motexafin gadolinium
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Madison, Wisconsin
Conditions
Pharyngitis, Tonsillitis
Interventions
Amoxicillin Pulsatile Release Multiparticulate Tablet (drug)
Drug
Lead sponsor
Advancis Pharmaceutical Corporation
Industry
Eligibility
12 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Advanced Solid Tumor
Interventions
ARV-6723, Pembrolizumab, SOC
Drug
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
New York, New York • Huntersville, North Carolina • San Antonio, Texas + 1 more
Conditions
Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma, Cyclin-dependent Kinase 12 Mutated Tumors, Basal Cell Carcinoma (Unresectable or Metastatic), Sarcomatoid Renal Cell Carcinoma, Clear Cell Ovarian or Endometrial Carcinoma, Anal Carcinoma, Squamous Cell Penile Carcinoma, DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)
Interventions
INCB099318
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Hackensack, New Jersey • Greenville, South Carolina • Nashville, Tennessee
Conditions
Acute Respiratory Tract Infection, Ear Infection, Throat Infection, Acute Respiratory Tract Infections, Common Cold
Interventions
Tele-Otoscope Enabled Primary Care, eBook-supported primary care
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Months to 24 Months
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Conditions
Anesthesia, Endotracheal
Interventions
Direct Laryngoscope (DL), Video laryngoscope (VL), Endotracheal Tube (ETT) 180
Device · Procedure
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 90 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Nasopharyngeal Cancer, EBV Infections
Interventions
EBV specific CTL Infusion, Anti CD45 monoclonal antibody
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Houston, Texas
Conditions
Pharyngitis
Interventions
valdecoxib, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
2
States / cities
Storrs, Connecticut • Boca Raton, Florida
Conditions
Intratracheal Intubation, Laryngoscopes, Postoperative Care, Risk Assessment
Interventions
Macintosh/Miller Laryngoscope, Glidescope Laryngoscope
Device
Lead sponsor
Jason Ngo, B.S.
Other
Eligibility
18 Years to 80 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Albany, New York
Conditions
FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Mutation, Head and Neck Squamous Cell Carcinoma, Human Papillomavirus Infection, Recurrent Head and Neck Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
Interventions
BGJ398
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Recurrent Tonsillitis, Obstructive Sleep Apnea, Sleep Disordered Breathing, Adverse Reaction to Drug
Interventions
Ibuprofen, Hydrocodone-Acetaminophen
Drug
Lead sponsor
Emory University
Other
Eligibility
4 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Pharyngitis
Interventions
Ibuprofen
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
12 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Albany, New York
Conditions
Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Nasopharyngeal Cancer, Nasopharyngeal Cancer Stage
Interventions
Intensity-Modulated Radiation Therapy (IMRT), Radiographic Imaging, Biospecimen Collection
Radiation · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
San Francisco, California
Conditions
Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer
Interventions
Utomilumab, ISA101b
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas